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Hong Kong SAR, China
Objectives The objective of this study was to determine if adding spironolactone to an angiotensin II receptor blocker im-
proves left ventricular (LV) function, mass, and volumes in chronic heart failure.
Background Add-on spironolactone therapy substantially improves clinical outcomes among patients with severe heart failure
(HF) on standard therapy. However, the value of combining spironolactone with an angiotensin II receptor
blocker on LV reverse remodeling in mild-to-moderate systolic HF is unclear.
Methods Fifty-one systolic HF patients with left ventricular ejection fraction (LVEF)40% were randomly assigned to receive
1-year treatment of candesartan and spironolactone (combination group) or candesartan and placebo (control group).
Reverse remodeling was assessed by serial cardiac magnetic resonance imaging and echocardiographic tissue Dopp-
ler imaging (TDI).
Results There were significant improvements in LVEF (35  3% vs. 26  2%, p  0.01) and reduction of LV end-
diastolic volume index (121  16 ml/m2 vs. 155  14 ml/m2, p  0.001), end-systolic volume index (88  17
ml/m2 vs. 120  15 ml/m2, p  0.0005), and LV mass index (81  6 g/m2 vs. 93  6 g/m2, p  0.002) in
the combination group at 1 year. In addition, there was significant increase in peak basal systolic velocity and
strain by TDI, decrease in index of filling pressure, and increase in cyclic variation integrated backscatter. In the
control group, there were no significant changes in all these parameters after 1 year.
Conclusions The addition of spironolactone to candesartan has significant beneficial effects on LV reverse remodeling in pa-
tients with mild-to-moderate chronic systolic HF. (J Am Coll Cardiol 2007;50:591–6) © 2007 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.062w
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pxcess aldosterone is well known to have diverse deleterious
ffects in systolic heart failure (HF) patients (1). Previous
tudies have established the beneficial role of the aldosterone
eceptor blocker spironolactone in treating patients with severe
F (2), and there is evidence suggesting that aldosterone
breakthrough” occurs that might attenuate the cardioprotec-
ive effects of long-term angiotensin-converting enzyme
ACE) inhibitor monotherapy (3,4). Similar concerns regard-
ng aldosterone “breakthrough” with angiotensin II receptor
locker (ARB) monotherapy have been raised, although the
esults from previous studies are conflicting (5,6). In fact,
rom the *Division of Cardiology, Department of Medicine and Therapeutics, and
he †Department of Diagnostic Radiology and Organ Imaging, Prince of Wales
ospital, The Chinese University of Hong Kong, Hong Kong SAR, China. Takeda
Hong Kong) Ltd. donated 25% of the study costs to support this study.a
Manuscript received January 24, 2007; revised manuscript received March 9, 2007,
ccepted March 12, 2007.hether spironolactone might exert an additive beneficial effect
o that of ARB on left ventricular (LV) function and reverse
emodeling in patients with mild-to-moderate systolic HF is
nknown.
See page 597
Therefore, we investigated the additive beneficial effects
f combining candesartan with spironolactone on reverse
V remodeling with serial cardiac magnetic resonance
maging (CMR) and tissue Doppler imaging (TDI).
ethods
tudy protocol and randomization. This was a prospective,
andomized, double-blind, placebo-controlled study. Eligible
atients with left ventricular ejection fraction (LVEF) 40%
nd receiving ACE inhibitors more than 6 months were
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inhibitors with candesartan 8 mg
and spironolactone 25 mg once
daily (combination group) or can-
desartan 8 mg and a matching
identical placebo once daily (con-
trol group) over a 1-year study
period. According to the study
protocol, enrolled patients under-
went serial CMR, echocardiogra-
phy, and clinical assessments and
laboratory tests (Fig. 1).
Patients. Eligible patients were
receiving standard anti-HF treat-
ment except for potassium-sparing
diuretics before randomization.
Dosages of these background
medications except diuretics were
not allowed to change after ran-
domization. Patients were ex-
cluded if they had significant val-
vular heart disease; congenital
eart disease; any life-threatening disease with limited life
xpectancy; or standard contraindications for CMR examina-
ion, creatinine concentration 200 mol/l, potassium level
Figure 1 Flow Chart Depicting the Design of the Study
ACEI  angiotensin-converting enzyme inhibition; CMR  cardiac magnetic resona
EF  ejection fraction; ETT  exercise treadmill time; NYHA  New York Heart As
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin II
receptor blocker
CMR  cardiac magnetic
resonance imaging
CVIB  cyclic variation of
integrated backscatter
HF  heart failure
LV  left
ventricle/ventricular
LVEDVI  left ventricular
end-diastolic volume index
LVEF  left ventricular
ejection fraction
LVESVI  left ventricular
end-systolic volume index
TDI  tissue Doppler
imaging5 mmol/l, and a history of allergy or side-effect with
pironolactone. All patients gave written informed consent.
he institutional ethics committee approved the study
rotocol.
MR. All CMR were performed with a 1.5-T scanner
Sonata, Siemens, Erlangen, Germany). Cine imaging with
teady state precession sequence were performed. Raw images
ere processed by manual outlining of the endocardial and
picardial borders at end-diastolic and end-systolic frames.
nalysis of LVEF, left ventricular end-systolic volume index
LVESVI) and left ventricular end-diastolic volume index
LVEDVI), and LV mass indexes by CMR were calculated
ith Simpson’s rule.
DI and strain imaging by echocardiography. Echocar-
iograms were performed with a standard ultrasound ma-
hine (Vivid 5 and Vivid 7, GE Vingmed, Horten, Nor-
ay). The TDI and strain imaging were acquired as
reviously described (7). Myocardial longitudinal velocity
nd deformation curves were obtained, and peak systolic
elocity (Sm) or strain during the ejection phase as well as
arly diastolic velocity (Em) were measured. The filling
ressure was estimated by the ratio of transmitral early
iastolic Doppler velocity (E) to Em measured at the basal
eptal segment (E/Em) (8).
aging;
on.nce im
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August 14, 2007:591–6 Spironolactone With ARB for HFntegrated backscatter imaging. Integrated backscatter
maging was acquired with parasternal long-axis view as
reviously described (9). The magnitude of cyclic variation
f integrated backscatter (CVIB) was defined as the differ-
nce between the minimal and maximal values in a cardiac
ycle. The final data were presented as mean value of the
eptum and posterior wall.
tatistical analysis. The study had a 90% power to detect
n 8% difference in LVEF and volume with a minimum
f 20 subjects in each group with 2-sided alpha of 0.05,
ssuming an SD of 8% for the CMR measurement of
VEF and LV volumes. All continuous values were
xpressed as mean  SE. Comparisons of the baseline
haracteristics between groups were performed with the
earson chi-square test for categorical variables. Com-
arisons within treatment group for CMR volumetric
ariables at baseline and 26 and 52 weeks were per-
ormed by paired t test. A repeated measure analysis of
ariance (ANOVA) for trends were used to assess treat-
ent effect on variables between treatment groups
elated to volumetric changes and ventricular remodeling.
value of p  0.05 was considered statistically signifi-
ant. SPSS version 13 was used (SPSS Inc., Chicago,
aseline Clinical Characteristics of the Patients
Table 1 Baseline Clinical Characteristics of the Patients
Candesartan 
Spironolactone
(n  23)
Candesartan 
Placebo
(n  25) p Value
Age (yrs) 61.4 12.3 65.0 0.6 0.29
Female/male (%) 3 (13.0)/20 (87.0) 5 (20.0)/20 (80.0) 0.70
Body mass index (kg/m2) 25.5 2.9 25.3 3.5 0.88
Hypertension (%) 7 (30.4) 10 (40.0) 0.56
History of coronary artery
disease (%)
8 (34.8) 11 (44.0) 0.57
Previous myocardial infarction
(%)
7 (30.4) 14 (56.0) 0.09
Coronary artery
revascularization (%)
4 (17.4) 9 (36.0) 0.20
Hyperlipidemia (%) 13 (56.5) 14 (56.0) 1.0
Diabetes (%) 6 (26.1) 8 (32.0) 0.75
Current cigarette
smoking (%)
3 (13.0) 3 (12.0) 1.0
Previous cigarette smoking (%) 12 (52.2) 12 (48.0) 1.0
Primary etiology of HF
Ischemic heart disease (%) 11 (47.8) 16 (64.0) 0.38
Hypertension (%) 1 (4.3) 2 (8.0) 1.0
Dilated cardiomyopathy (%) 11 (47.8) 7 (28.0) 0.23
Background medications
Diuretics (%) 11 (47.8) 17 (68.0) 0.24
Beta-blocker (%) 16 (69.6) 18 (72.0) 1.0
Nitrates (%) 14 (60.9) 10 (40.0) 0.25
Aspirin (%) 15 (65.2) 20 (80.0) 0.34
Statins (%) 9 (39.1) 15 (60.0) 0.25
ACEI before
randomization (%)
23 (100.0) 25 (100.0) 1.0
ll p  NS for intergroup difference at baseline.
ACEI  angiotensin-converting enzyme inhibition; HF  heart failure.llinois).

tesults
total of 51 patients were enrolled in the study. Of those,
8 patients were randomized and completed 1 year follow-
p. Patients’ baseline clinical characteristics are summarized
n Table 1. There were no statistically significant differences
etween the 2 groups in terms of demographic data, etiology
f HF, and background medications at baseline and over the
ourse of follow-up period.
ffects on LVEF, volumes, and mass index by CMR. The
Vs were dilated at baseline in both groups, indicating
evere LV adverse remodeling. There were no significant
ifferences of all baseline CMR parameters between the 2
roups (Table 2). The combination group had significant
mprovement of LVEF at 26 weeks (Table 3) and further
mproved at 52 weeks (Table 4). Furthermore, there were
ignificant reductions in LVEDVI, LVESVI, and LV
ass index after 1 year of treatment in the combination
roup (all p  0.05) (Table 4). In fact, the reduction of
olume indexes occurred as early as 26 weeks. In contrast,
ll these parameters were unchanged in the control group
Tables 3 and 4). The intergroup differences for changes
n LVEF, LVEDVI, and LVESVI at 52 weeks were
tatistically significant by repeated measure ANOVA for
rends (Fig. 2).
V long-axis function by TDI. The Sm and basal peak
ystolic strain increased significantly, and there was a
aseline CMR andchocardiographic Parameters (Mean  SEM)
Table 2 Baseline CMR andEchocardiographic Parameters (Mean  SEM)
Candesartan 
Spironolactone
(n  23)
Candesartan 
Placebo
(n  25) p Value
CMR at baseline LVEF (%) 26 2 28 2 0.62
LVEDVI (ml/m2) 154.68 14.21 138.03 10.29 0.34
LVESVI (ml/m2) 120.30 14.74 101.96 9.42 0.29
LV mass (g) 163.01 11.87 157.31 13.83 0.76
LVMI (g/m2) 93.22 5.93 91.75 6.74 0.87
Echocardiography at baseline
E (m/s) 0.77 0.06 0.68 0.05 0.25
A (m/s) 0.81 0.06 0.75 0.04 0.41
E/A 1.08 0.15 1.00 0.15 0.94
IVRT (ms) 110.39 8.65 108.90 5.47 0.88
DT (ms) 216.87 21.81 217.02 15.52 1.0
Sm (cm/s) 3.38 0.16 3.53 0.22 0.6
Em (cm/s) 2.91 0.34 2.93 0.29 0.96
E/Em 33.14 5.25 33.99 0.09 0.94
CVIB (dB) 10.58 0.69 11.80 0.76 0.24
Ts-SD (ms) 42.74 3.44 37.64 3.28 0.29
Systolic strain, basal (%) 12.96 1.00 13.97 1.05 0.49
Systolic strain, mid (%) 9.77 0.76 9.22 1.07 0.67
ll p  NS for intergroup difference at baseline.
A  peak atrial inflow velocity; CMR  cardiac magnetic resonance imaging; CVIB  cyclic
ariation of integrated backscatter; DT  deceleration time; E  peak early diastolic transmitral
elocity; E/A  ratio of peak early to late atrial mitral inflow velocities; Em  peak early diastolic
yocardial velocity; E/Em  ratio of transmitral E to Em measured at the basal septal segment;
VRT isovolumic ventricular relaxation time; LVEDVI left ventricular end-diastolic volume index;
VEF  left ventricular ejection fraction; LVESVI  left ventricular end-systolic volume index; LVMI
left ventricular mass index; Sm peak systolic velocity; Ts-SD standard deviation of the time
o peak myocardial velocity from 12 segments.
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Spironolactone With ARB for HF August 14, 2007:591–6arked reduction in E/Em only in the combination group
Tables 3 and 4). These echocardiographic parameters were
nchanged in the control group.
VIB. The CVIB increased significantly in the combina-
ion group but not in the control group. This suggested a
eduction in myocardial fibrosis after 52 weeks of combina-
ion therapy (Table 4).
ew York Heart Association (NYHA) functional class,
uality of life, and 6-min walking test. The quality of life
core was improved similarly in both groups. None of the
atients had deterioration in NYHA functional class or
ignificant improvement in the 6-min hall-walk test at
he end of the study (Table 5). Two patients in the
ombination group were hospitalized for congestive HF
ompared with 4 in the placebo group (p  NS),
lthough this study was not powered to investigate the
ffect on hospital stays or mortality.
afety and tolerability of candesartan/spironolactone.
here were 3 patients prematurely withdrawn from the
tudy; 1 patient in the combination group and 1 patient
n the control group had sustained hypotension. After 1
ear, the mean systolic blood pressure decreased in the
ombination group (127  3 mm Hg to 117  3 mm Hg,
 0.05). One patient in the combination group had
yperkalemia (5.8 mmol/l) leading to withdrawal from
tudy. The mean serum creatinine level increased in
he combination group (from 114  23 mol/l to 138 
9 mol/l, p  0.05), although none of the patients
eached a level that necessitated withdrawal from the
MR and Echocardiographicesults (Mean  SEM) at 26 Weeks
Table 3 CMR and EchocardiographicResults (Mean  SEM) at 26 Weeks
Candesartan 
Spironolactone
(n  23)
Candesartan 
Placebo
(n  25)
CMR at 26 weeks
LVEF (%) 31 3* 30 2
LVEDVI (ml/m2) 130.01 15.13* 136.84 9.49
LVESVI (ml/m2) 98.32 13.98* 98.76 9.24
LV mass (g) 154.30 12.30 159.72 13.89
LVMI (g/m2) 87.32 6.16 91.92 6.30
Echocardiography at 26 weeks
E (m/s) 0.61 0.04† 0.68 0.05
A (m/s) 0.88 0.05 0.88 0.05
E/A 0.73 0.06† 0.89 0.10
IVRT (ms) 122.15 7.67 122.56 5.88
DT (ms) 239.86 16.38 220.58 14.22
Sm (cm/s) 3.86 0.21 3.48 0.20
Em (cm/s) 3.18 0.32 2.99 0.24
E/Em 21.37 0.02† 25.83 0.03
CVIB (dB) 12.93 0.86† 12.50 0.76
Ts-SD (ms) 39.16 3.51 45.51 2.90
Systolic strain, basal (%) 16.60 0.95† 15.14 0.88
Systolic strain, mid (%) 12.35 1.04† 11.02 1.03
ll p  NS for intergroup difference at 26 weeks. *p  0.01 versus baseline; †p  0.05.
Abbreviations as in Table 2.tudy.
Aiscussion
his clinical study addresses the beneficial role of dual
lockade of angiotensin II and aldosterone receptors on the
everse remodeling process in chronic mild-to-moderate
ystolic HF. We were able to demonstrate that combination
herapy of candesartan and spironolactone produced sub-
tantial reverse remodeling in HF, despite maximal medical
herapy including beta-blocker medications and in predom-
nantly NYHA functional class II patients. Dual blockade
chieves a significant reduction in LV size, improvement in
verall systolic function, and reversal of LV hypertrophy.
he improvement of CVIB might also reflect the reduction
f myocardial fibrosis. These beneficial effects are apparent
arly after initiation of therapy, and further improvement
ccurred throughout the entire 1-year treatment period
rrespective of HF etiology. Our study provides a rationale
or the use of this combination therapy in selected HF
atients. The potential role of dual blockade in further
eduction of hospital stays for HF or mortality needs to be
ddressed by a larger clinical trial.
We postulate that one of the cardioprotective mecha-
isms of dual blockade is possibly through reduction of
yocardial fibrosis and reverse remodeling (10). The com-
ination therapy of spironolactone and candesartan resulted
n reduction of LV volumes and myocardial fibrosis in an
nimal study (11). In this study, CVIB assessment showed
mprovement after combination therapy similar to that
bserved in hypertensive HF and in keeping with the
ocumented antifibrotic action of aldosterone antagonists
een experimentally (12).
chocardiographic and CMResults (Mean  SE) at 52 Weeks
Table 4 Echocardiographic and CMRResults (Mean  SE) at 52 Weeks
Candesartan 
Spironolactone
(n  23)
Candesartan 
Placebo
(n  25)
CMR at 52 weeks
LVEF (%) 35 3* 31 2
LVEDVI (ml/m2) 121.10 15.76* 135.13 10.60
LVESVI (ml/m2) 88.14 17.10* 97.51 10.16
LV mass (g) 144.60 13.46† 157.39 8.67
LVMI (g/m2) 80.96 6.48† 91.69 4.65
Echocardiography at 52 weeks
E (m/s) 0.62 0.04† 0.64 0.05
A (m/s) 0.85 0.04 0.84 0.05
E/A 0.76 0.06† 0.83 0.09
IVRT (ms) 118.87 6.24 114.56 4.96
DT (ms) 251.89 15.71 249.29 16.14
Sm (cm/s) 4.04 0.31† 3.62 0.20
Em (cm/s) 3.46 0.27 3.13 0.30
E/Em 19.94 0.02* 24.63 0.03
CVIB (dB) 13.38 1.00† 10.90 0.75
Ts-SD (ms) 37.42 3.69 46.71 3.70
Systolic strain, basal (%) 16.10 1.14† 14.98 0.87
Systolic strain, mid (%) 11.34 0.86 11.69 0.76ll p  NS for intergroup difference at 52 weeks. *p  0.01 versus baseline; †p  0.05.
Abbreviations as in Table 2.
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August 14, 2007:591–6 Spironolactone With ARB for HFAnother potential beneficial mechanism of combination
herapy is more complete inhibition of the renin angiotensin
ldosterone system (RAAS). Nonsustained suppression of
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Figure 2 Serial Changes of LVEF,
LVEDVI, and LVESVI by CMR
CMR  cardiac magnetic resonance imaging; LVEDVI  left ventricular end-
diastolic volume index; LVEF  left ventricular ejection fraction; LVESVI  left
ventricular end-systolic volume index.he RAAS is seen after chronic therapy of beta-blocker (13),
gCE inhibitor medications, or ARBs, suggesting that
ennin and aldosterone “breakthrough” do occur after the
hronic use of current standard anti-HF therapy. Thus, it
an be advised that an aldosterone antagonist should be
dded when an ARB is used alone in treating a patient with
ystolic HF, because the impact on reverse remodeling is
onsiderable. However, 1 patient (4%) who was taking a
ombination of an ARB, beta-blocker, and spironolactone
eveloped significant hyperkalemia. Close monitoring of
otassium level, careful patient selection, and titration of
edication dosage are recommended.
The dose of candesartan used in this study was relatively
odest compared with the higher doses used in the
HARM (Candesartan in Heart Failure–Assessment of
ortality and morbidity) trial (14). But in the CHARM
tudy, only about two-thirds of the study population toler-
ted the target dose of 32 mg because of hypotension and
nly 24% of patients in the CHARM-Alternative arm were
aking spironolactone (15). Lower-dose candesartan has
een proven to be efficacious (16). Candesartan 8mg was
onsidered a reasonable therapeutic dose, and we were
oncerned about the potential risk of hyperkalemia when
ombining spironolactone with higher doses of candesartan.
f course, our study cannot answer whether spironolactone
dded to an ARB in larger doses will produce a different
esult with respect to LV reverse remodeling or the inci-
ence of adverse events. We have provided evidence of a
ignificant beneficial effect on LV reverse remodeling with a
elatively low adverse event rate with a low-dose combina-
OL and ETT Results (Mean  SE)
Table 5 QOL and ETT Results (Mean  SE)
Candesartan 
Spironolactone
(n  23)
Candesartan 
Placebo
(n  25)
QOL
Baseline 23.78 3.34 20.72 2.72
26 weeks 15.09 2.89* 12.54 2.06*
52 weeks 11.86 2.74* 8.71 1.35*
26-week change (%) 8.86 1.73* (42.8%) 7.13 0.44† (37.1%)
52-week change (%) 12.30 2.07† (58.5%) 10.96 1.91† (54.0%)
ETT
Baseline 1,207 61 1,239 48
26 weeks 1,291 56 1,282 41
52 weeks 1,274 58 1,320 48
26-week change (%) 79.95 16.19 (7.19%) 22.46 14.25 (2.38%)‡
52-week change (%) 69.70 14.73 (6.23%) 59.50 17.94 (4.85%)
NYHA
Baseline, class I (%) 4 (17.4) 3 (12)
Class II (%) 16 (69.6) 18 (72.0)
Class III (%) 3 (13.0) 4 (16.0)
26-week, class I (%) 10 (45.5) 13 (54.2)
Class II (%) 12 (54.5) 10 (41.7)
Class III (%) 0 1 (4.2)
52-week, class I (%) 12 (62.5) 15 (62.5)
Class II (%) 9 (37.5) 9 (37.5)
p 0.05; †p 0.01 baseline versus 26-/52-week; ‡p 0.05 combination group versus placebo
roup.
ETT  exercise treadmill time; NYHA  New York Heart Association; QOL  quality of life.
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Spironolactone With ARB for HF August 14, 2007:591–6ion therapy in carefully selected patients. The optimal
osage of combining candesartan with spironolactone
waits future studies.
tudy limitations. The sample size was relatively small but
ad adequate power, because we used CMR for volumetric
easurements to assess LV reverse remodeling (17). There was
trend in the combination group for lower EF, younger age,
ess hypertension, coronary artery disease, myocardial infarc-
ion, revascularization, more nonischemic etiology, and a 20%
ess use of diuretic and statin in the combination group, but all
hese parameters did not reach statistical significance (p 
.05). The positive results achieved in this study were not likely
ue to fluid overload at baseline, because diuretic dosage was
ptimized before recruitment and there was no indication to
lter diuretic dosages during the study. Furthermore, the
hanges in LV dimensions and LVEF were used to assess
emodeling in this study. Although LVEF might be influenced
y transient loading conditions, the dimensional and volumet-
ic changes probably reflect structural modifications occurring
n the myocardium. The role of statin therapy on LV remod-
ling in HF patients is still controversial.
onclusions
he present study demonstrates that in patients with
hronic mild-to-moderate systolic HF, adding spironolac-
one to an ARB produces incremental beneficial effects on
V reverse remodeling and LV function. Further larger
linical studies are needed to determine whether spirono-
actone in conjunction with an ARB can reduce mortality or
ospital stays for congestive HF.
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